Premium
Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre‐existing motor neurone disease
Author(s) -
Bortz H.,
Coutsouvelis J.,
Corallo C. E.,
Spencer A.,
Patil S.
Publication year - 2015
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12293
Subject(s) - medicine , neurotoxicity , exacerbation , peripheral neuropathy , lymphoma , regimen , chemotherapy , oncology , neurooncology , surgery , toxicity , diabetes mellitus , endocrinology
Summary What is known and objective Intensive chemotherapy for treatment of Burkitt's lymphoma ( BL ) – a high‐grade lymphoproliferative disorder ( LPD ) – can cause neurotoxicity. An association between motor neurone disease ( MND ) and LPD s has previously been described, but there is a lack of recommendations available to guide management of such patients. This report aims to describe suitable management of BL in a patient with MND . Case description A 66‐year‐old woman with a history of MND affecting her limbs was diagnosed with bulky, extranodal, high‐risk gastric BL . Standard chemotherapy is with multiple non‐cross‐resistant cytotoxic agents. To avoid exacerbation of neuropathy, six cycles of a modified regimen was planned, aiming to minimize exposure to the most neurotoxic agents. A PET ‐ FDG ‐negative remission was obtained at 12 months, without the signs of central neurotoxicity, peripheral neuropathy or muscle weakness. What is new and conclusion High‐intensity chemotherapy, minimizing known neurotoxic agents, was delivered safely and effectively in a patient with BL and pre‐existing MND . More case descriptions are required to guide management decisions.